The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.
Health Professionals
Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced Melanoma
Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.
Longer Time Until Recurrence Associated With Better Melanoma Outcomes
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
WEDNESDAY, Oct. 2, 2024 (HealthDay News) — Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.